Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
Solid track record and fair value.
Share Price & News
How has Ligand Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LGDN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LGDN underperformed the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: LGDN underperformed the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is Ligand Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Ligand Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: LGDN (€92) is trading above our estimate of fair value (€56.34)
Significantly Below Fair Value: LGDN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LGDN is good value based on its PE Ratio (3x) compared to the Biotechs industry average (43.8x).
PE vs Market: LGDN is good value based on its PE Ratio (3x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: LGDN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: LGDN is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.5x).
How is Ligand Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGDN's earnings are forecast to decline over the next 3 years (-162.7% per year).
Earnings vs Market: LGDN's earnings are forecast to decline over the next 3 years (-162.7% per year).
High Growth Earnings: LGDN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: LGDN's revenue (9.8% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: LGDN's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGDN's Return on Equity is forecast to be high in 3 years time
How has Ligand Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGDN has a high level of non-cash earnings.
Growing Profit Margin: LGDN's current net profit margins are higher than last year (57%).
Past Earnings Growth Analysis
Earnings Trend: LGDN's earnings have grown significantly by 50.7% per year over the past 5 years.
Accelerating Growth: LGDN's earnings growth over the past year (339.1%) exceeds its 5-year average (50.7% per year).
Earnings vs Industry: LGDN earnings growth over the past year (339.1%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: LGDN's Return on Equity (82%) is considered outstanding.
Return on Assets
Return on Capital Employed
How is Ligand Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LGDN's short term assets ($1.1B) exceed its short term liabilities ($17.0M).
Long Term Liabilities: LGDN's short term assets ($1.1B) exceed its long term liabilities ($685.1M).
Debt to Equity History and Analysis
Debt Level: LGDN's debt to equity ratio (83.2%) is considered high.
Reducing Debt: LGDN's debt to equity ratio has reduced from 799.9% to 83.2% over the past 5 years.
Debt Coverage: LGDN's debt is not well covered by operating cash flow (1.7%).
Interest Coverage: Insufficient data to determine if LGDN's interest payments on its debt are well covered by EBIT.
Inventory Level: LGDN has a low level of unsold assets or inventory.
Debt Coverage by Assets: LGDN's debt is covered by short term assets (assets are 1.8x debt).
What is Ligand Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate LGDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LGDN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGDN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGDN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LGDN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Higgins (49yo)
Mr. John L. Higgins has been the Chief Executive Officer at Ligand Pharmaceuticals Incorporated since January 16, 2007. He serves as the President and Chief Executive Officer of Moonstone Acquisition, Inc. ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD6.31M) is above average for companies of similar size in the German market ($USD1.47M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||13.1yrs||US$6.31m||1.17% $19.3m|
|President & COO||5.1yrs||US$3.32m||0.88% $14.4m|
|Executive VP of Finance & CFO||4.5yrs||US$2.67m||0.15% $2.5m|
|Senior VP||12.8yrs||US$1.74m||0.30% $4.9m|
|Senior Vice President of Investor Relations||0yrs||no data||no data|
|Director of Corporate Development||0yrs||no data||no data|
|Senior VP of Human Resources||13.1yrs||no data||no data|
|Senior Vice President of Biology & Scientific Affairs||2.1yrs||no data||no data|
|Senior VP of Technical Operations - CAPTISOL||2.1yrs||no data||no data|
Experienced Management: LGDN's management team is seasoned and experienced (5.1 years average tenure).
|CEO & Executive Director||13.1yrs||US$6.31m||1.17% $19.3m|
|Independent Chairman||12.9yrs||US$363.37k||0.15% $2.5m|
|Independent Director||12.9yrs||US$343.37k||0.28% $4.6m|
|Independent Director||9yrs||US$335.87k||0.14% $2.2m|
|Independent Director||9.3yrs||US$338.37k||0.15% $2.5m|
|Independent Director||11.5yrs||US$353.37k||0.13% $2.2m|
|Independent Director||13.4yrs||US$345.87k||0.41% $6.8m|
|Scientific Advisor||0yrs||no data||no data|
|Director||0.3yrs||no data||0.0081% $134.5k|
|Independent Director||2.5yrs||US$338.37k||0.013% $210.5k|
Experienced Board: LGDN's board of directors are seasoned and experienced ( 11.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ligand Pharmaceuticals Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Ligand Pharmaceuticals Incorporated
- Ticker: LGDN
- Exchange: DB
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.781b
- Listing Market Cap: US$1.650b
- Shares outstanding: 17.56m
- Website: https://www.ligand.com
Number of Employees
- Ligand Pharmaceuticals Incorporated
- 3911 Sorrento Valley Boulevard
- Suite 110
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LGND||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 1994|
|LGDN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1994|
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 20:35|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.